<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Greenberg Greenwood | Activity</title>
	<link>https://www.catswannabecats.com/members/epochgalley9/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/epochgalley9/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Greenberg Greenwood.</description>
	<lastBuildDate>Wed, 01 Jul 2026 18:37:05 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">3ea1338f81c4ca01ef4190119a3f7988</guid>
				<title>Greenberg Greenwood posted an update: orbidity and mortality. These findings should help [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23268/</link>
				<pubDate>Sun, 08 Jun 2025 07:54:39 -0400</pubDate>

									<content:encoded><![CDATA[<p>orbidity and mortality. These findings should help clinicians balance the risks and benefits of transfusion before well-designed trials are conducted in this patient population.</p>
<p> Despite novel therapies, multiple myeloma (MM) remains an incurable malignancy, daratumumab (DARA) being a major game changer, may be a good option for&hellip;<span class="activity-read-more" id="activity-read-more-23268"><a href="https://www.catswannabecats.com/activity/p/23268/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b6f3e7f7f7504071125771a5b7ae46ac</guid>
				<title>Greenberg Greenwood posted an update: We will undertake a cost-effectiveness analysis taking both [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/10274/</link>
				<pubDate>Sun, 01 Jun 2025 00:09:35 -0400</pubDate>

									<content:encoded><![CDATA[<p>We will undertake a cost-effectiveness analysis taking both a health and social care and wider societal perspective. Semistructured interviews will be conducted with multiple stakeholders (ie, service users, paid/family carers, IST managers/staff) to investigate the experience of IST care as well as an online survey of referrers to capture their&hellip;<span class="activity-read-more" id="activity-read-more-10274"><a href="https://www.catswannabecats.com/activity/p/10274/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4bf07547a0424df89fd8242d31cc2c7c</guid>
				<title>Greenberg Greenwood became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/10173/</link>
				<pubDate>Sat, 31 May 2025 23:58:47 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>